CardioDx Sets Price Range on Planned IPO | GenomeWeb

NEW YORK (GenomeWeb News) – CardioDx today set the price range on its planned initial public offering and raised the maximum proposed aggregate offering price to $92.0 million.

In its amended Form S-1 filed with the US Securities and Exchange Commission, the Palo Alto, Calif.-based cardiovascular molecular diagnostics firm said it anticipates offering 5 million shares of its common stock at between $14 and $16 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.